Delivering on the GWAS promise: from genetic discoveries to novel drug targets for asthma

兑现 GWAS 承诺：从基因发现到哮喘新药物靶点

• 批准号: nhmrc : GNT1124501
• 负责人: A/Pr Manuel Ferreira
• 金额: $ 69.76万
• 依托单位国家: 澳大利亚
• 项目类别: Research Fellowships
• 财政年份: 2017
• 资助国家: 澳大利亚
• 起止时间: 2017-01-01 至 无数据
• 项目状态: 已结题
• 来源: https://researchdata.edu.au/delivering-gwas-promise-targets-asthma/1347415
• 关键词: Delivering; GWAS; promise; genetic; discoveries

The aim of this study is to identify new drug targets for asthma. This is important because for 6 in 10 asthma patients, current treatments do not adequately control disease symptoms and so these individuals are at a higher risk of having severe exacerbations. I propose that identifying asthma risk genes represents our best chance to identify novel drug targets for asthma. In this study, I will identify new asthma risk genes and test whether blocking these genes can alleviate disease symptoms.

本研究的目的是寻找新的哮喘药物靶点。这一点很重要，因为对于每10名哮喘患者中就有6名，目前的治疗方法不能充分控制疾病症状，因此这些人出现严重恶化的风险更高。我认为，确定哮喘风险基因是我们确定哮喘新药靶点的最佳机会。在这项研究中，我将发现新的哮喘风险基因，并测试阻断这些基因是否可以缓解疾病症状。